Cytokines News and Research

Latest Cytokines News and Research

Cytomegalovirus may cause high blood pressure

A new study suggests for the first time that cytomegalovirus (CMV), a common viral infection affecting between 60 and 99 percent of adults worldwide, is a cause of high blood pressure, a leading risk factor for heart disease, stroke and kidney disease.

15 May 2009

Discovery of major new treatment target in diseased arteries

Removing a single protein prevents early damage in blood vessels from triggering a later-stage, frequently lethal complication of atherosclerosis, according to research published online today in the journal Nature Medicine. By eliminating the gene for a signaling protein called cyclophilin A (CypA) from a strain of mice, researchers were able to provide complete protection against abdominal aortic aneurysm (AAA).

11 May 2009

Research looks at contact lens risks and benefits

Contact lenses are great for sight, but do they have an impact on general eye health? Researchers at the University of Alabama at Birmingham (UAB) School of Optometry are working to answer that question by analyzing tears.

6 May 2009

Mushrooms may boost the body's natural immune system

The potential for mushrooms to fight influenza is being examined following United States research suggesting the body's natural immune response against viral infections and tumours is boosted through the consumption of white button mushrooms.

6 May 2009

A more potent vaccine technology

Virginia Tech virologist Chris Roberts' goal is to develop a platform for a flu vaccine that allows rapid modifications to meet new strains of flu.

4 May 2009

Research looks at UVB therapy for psoriasis

Ultraviolet light is a proven treatment for psoriasis, one of humanity's oldest known diseases.

29 Apr 2009

Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies

Peregrine Pharmaceuticals, Inc. has reported that two preclinical studies presented during the AACR 100th Annual Meeting 2009 provided further confirmation of the immunomodulatory mechanisms contributing to the anti-tumor activity of its phosphatidylserine (PS) targeting antibodies.

22 Apr 2009

Human foetal stem cells can effectively be used to treat back leg ischaemic ulcers

Treatment of chronic wounds is a continuing clinical problem and socio-economic burden with diabetic foot ulcers alone costing the NHS £300 million a year.

20 Apr 2009

Laughter improves health

The connection between the body, mind and spirit has been the subject of conventional scientific inquiry for some 20 years.

20 Apr 2009

Brain metastases hijack neuron-supporting cells to resist chemotherapy

Cancer that spreads to other organs finds a particularly inviting hideout in the brain, where these metastases are usually far harder to treat than they are in other locations.

20 Apr 2009

Thymoquinone inhibits the development of pancreatic cancer

An herb recently found to kill pancreatic cancer cells also appears to inhibit development of pancreatic cancer as a result of its anti-inflammatory properties, according to researchers from the Kimmel Cancer Center at Jefferson.

20 Apr 2009

Scientists first evidence of cell-to-cell communication by amino acids

A team of researchers from the Massachusetts General Hospital Center for Engineering in Medicine (MGH-CEM) has found the first evidence of cell-to-cell communication by amino acids, the building blocks of proteins, rather than by known protein signaling agents such as growth factors or cytokines.

6 Apr 2009

Is telmisartan effective in treating non-alcoholic steatohepatitis?

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive liver disease leading to cirrhosis and hepatocellular carcinoma.

2 Apr 2009

Aerovance starts phase IIb clinical trial with Aerovant for uncontrolled asthma

Aerovance Inc. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate Aerovance's Phase IIb clinical trial, AeroTrial, of inhaled dry powder Aerovant in patients with uncontrolled asthma.

2 Apr 2009

New insights into how brain responds to viral infection

Scientists at Columbia University Mailman School of Public Health have discovered that astrocytes, supportive cells in the brain that are not derived from an immune cell lineage, respond to a molecule that mimics a viral infection using cellular machinery similar to that used by classical immune cells in the blood.

1 Apr 2009

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers.

30 Mar 2009

Researchers find direct link between oxidative stress and inflammatory signals in the blood

The finding could lead to improved strategies for preventing several diseases by including antioxidants in the diet and for reducing the impact of inflammation in critically ill patients by adding cysteine to intravenous or tube feeding.

30 Mar 2009

Biothera receives approval to launch two lung cancer trials

German regulatory authorities have granted approval to Biothera to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGGÂ® administered in combination with monoclonal antibodies and chemotherapy in patients with non-small cell lung cancer (NSCLC), the company announced today.

12 Mar 2009

Scientists unveil a new path towards better immune responses

The immune response can protect us from basically any invader but it can also create disease - like it happens in autoimmunity where it attacks the own body - so to understand its regulation is an important tool to assure its proper functioning.

11 Mar 2009

Novel anti-inflammatory therapy protects lungs from runaway inflammation

A novel anti-inflammatory therapy designed by Vanderbilt University Medical Center investigators prevents acute lung injury in mice exposed to an inflammation-causing toxin, the researchers report in the journal Molecular Therapy.

11 Mar 2009